Abstract: Antibodies capable of binding HLA-A2/Tyrosinase (TyrD) in an HLA restricted manner are provided. Specifically, the antibodies are capable of binding HLA-A2/TyrD369-377 in an HLA restricted manner. Further provided are complementary determining region (CDR) sequences of heavy chain and light chain of antibodies, and methods of using the antibodies for the treatment of cancer.

Abstract: Methods, systems and apparatuses may provide for technology that generates a point cloud model of an object depicted in image content associated with a plurality of physical cameras, generates a color projection of the point cloud model based on viewpoint information associated with a virtual camera, and excludes background color information from the color projection based on one or more segmentation masks associated with the object. The technology may also exclude peripheral information from the color projection based on at least one of the segmentation mask(s) and the viewpoint information.

Abstract: Affinity binding entities having TCRL binding domain and methods of their use are provided. More specifically these compositions bind HLA-A2/WT1+, HLA-A2/MAGE-A4, HLA-A2/MAGE-A9, HLA-A2/PAP or HLA-A2/TyrD+ cells and as such can be used in diagnostics and therapy.

Abstract: Methods, systems and apparatuses may provide for technology that generates a point cloud model of an object depicted in image content associated with a plurality of physical cameras, generates a color projection of the point cloud model based on viewpoint information associated with a virtual camera, and excludes background color information from the color projection based on one or more segmentation masks associated with the object. The technology may also exclude peripheral information from the color projection based on at least one of the segmentation mask(s) and the viewpoint information.

Abstract: Affinity binding entities having TCRL binding domain and methods of their use are provided. More specifically these compositions bind HLA-A2/WT1+, HLA-A2/MAGE-A4, HLA-A2/MAGE-A9, HLA-A2/PAP or HLA-A2/TyrD+ cells and as such can be used in diagnostics and therapy.

Abstract: Embodiments are generally directed to neural network based patch blending for immersive video. An embodiment of a system includes one or more processor cores; a memory to store data for images in immersive video; and a neural network training framework. The neural network training framework is to generate a trained neural network for blending of a view of an object with patches generated for one or more detected occlusions for the object.

Abstract: Antibodies capable of binding HLA-A2/Tyrosinase (TyrD) in an HLA restricted manner are provided. Specifically, the antibodies are capable of binding HLA-A2/TyrD369-377 in an HLA restricted manner. Further provided are complementary determining region (CDR) sequences of heavy chain and light chain of antibodies, and methods of using the antibodies for the treatment of cancer.

Abstract: An apparatus to facilitate processing video bit stream data is disclosed. The apparatus includes one or more processors to receive point cloud data included in the video bit stream data to be projected into two or more angles and encode multiple projections for a point cloud point upon a determination that the point cloud point will be included in patches in two or more of the multiple projections.

Abstract: Embodiments are generally directed to neural network based patch blending for immersive video. An embodiment of a system includes one or more processor cores; a memory to store data for images in immersive video; and a neural network training framework. The neural network training framework is to generate a trained neural network for blending of a view of an object with patches generated for one or more detected occlusions for the object.

Abstract: An antibody capable of binding, with a human major histocompatibility complex (MHC)-restricted specificity, a MHC being complexed with an HLA-restricted peptide antigen is provided. The antibody having a binding specificity dictated by at least 4 amino acid residues in said HLA-restricted peptide such that at least 70% reduction in binding of said antibody to said complex is observed when each of said at least 4 amino acid residues is substituted as determined by FACS of cells loaded with said HLA-restricted peptide comprising said substitution, said at least 4 amino acid residues not being anchor residues.

Abstract: A method, apparatus and product for detecting corresponding paths in combinationally equivalent circuit designs. The method comprising: obtaining a first circuit design and a second circuit design, the first and second circuit designs have corresponding sets of input and output elements; obtaining a path in the first circuit design, the path commencing in an input element and ending in an output element, wherein the input element and the output element are connected by combinational logic elements; automatically extracting, by a computer, a sensitization function of the path in the first circuit design; and automatically determining, by the computer, one or more paths in the second circuit design which are sensitized by the sensitization function of the path.

Abstract: A method, apparatus and product for detecting corresponding paths in combinationally equivalent circuit designs. The method comprising: obtaining a first circuit design and a second circuit design, the first and second circuit designs have corresponding sets of input and output elements; obtaining a path in the first circuit design, the path commencing in an input element and ending in an output element, wherein the input element and the output element are connected by combinational logic elements; automatically extracting, by a computer, a sensitization function of the path in the first circuit design; and automatically determining, by the computer, one or more paths in the second circuit design which are sensitized by the sensitization function of the path.

Abstract: The present invention relates to methods for detecting, prognosing and staging cancers, in particular cancers of the gastrointestinal tract. The methods of the invention comprise detecting specific protein markers in a tissue of interest, wherein the detected levels thereof may be indicative of pre-cancerous or cancerous tissue, or the stage or prognosis of a cancer. Further provided are methods of treating cancer, and cancer detection kits.

Abstract: The present invention relates to methods for detecting, prognosing and staging cancers, in particular cancers of the gastrointestinal tract. The methods of the invention comprise detecting specific protein markers in a tissue of interest, wherein the detected levels thereof may be indicative of pre-cancerous or cancerous tissue, or the stage or prognosis of a cancer. Further provided are methods of treating cancer, and cancer detection kits.

Abstract: A method for design verification includes running a simulation of a design in a simulation environment, which comprises a stimuli generator for providing inputs to the design during the simulation. Respective measures of quality are computed for at least some of the simulation states in a sequence of states generated by the environment. State data are saved with respect to at least one of the simulation states. The state data include indications both of the respective simulated state and of the respective environment state. Responsively to the respective measures of quality, the saved state data are recalled so as to restart the simulation from the at least one of the simulation states by returning the design to the respective simulated state and returning the simulation environment to the respective environment state.

Abstract: A method for design verification includes receiving a software model of a design of a system under evaluation, and providing a property, which is dependent on a specified variable having a predefined range of values. The property applies to all states of the system for any selected value among the values of the variable within the predefined range. The property is processed so as to generate a checker program for detecting a violation of the property. A simulation of the system is then run using the software model together with the checker program.

Abstract: A method for verifying software source code that includes references to program variables includes processing the source code to derive a set of next-state functions representing control flow of the source code. The references to the program variables in the source code are replaced with non-deterministic choices in the next-state functions. The next-state functions including the non-deterministic choices are restricted to produce a finite-state model of the control flow. The finite-state model is then verified to find an error in the source code.

Abstract: A method of identifying peptides originating from a particular cell type and being capable of binding to MHC molecules of a particular haplotype is disclosed. The method comprises obtaining a cell type expressing a soluble and secreted form of the MHC molecules of the particular haplotype; collecting the soluble and secreted form of the MHC molecules of the particular haplotype; and analyzing peptides bound to the soluble and secreted form of the MHC molecules of the particular haplotype, thereby identifying the peptides originating from the particular cell type and being capable of binding to MHC molecules of the particular haplotype.

Abstract: A method of identifying peptides originating from a particular cell type and being capable of binding to MHC molecules of a particular haplotype is disclosed. The method comprises obtaining a cell type expressing a soluble and secreted form of the MHC molecules of the particular haplotype; collecting the soluble and secreted form of the MHC molecules of the particular haplotype; and analyzing peptides bound to the soluble and secreted form of the MHC molecules of the particular haplotype, thereby identifying the peptides originating from the particular cell type and being capable of binding to MHC molecules of the particular haplotype.

Abstract: There are provided methods and apparatus for analyzing data from a plurality of secondary mass spectra. In one embodiment of the invention, sets of features in pairs of the secondary mass spectra are compared, in order to determine which of the pairs of secondary mass spectra meet a predetermined similarity criterion, depending on the sets of features. A group of the secondary mass spectra is formed, and the secondary mass spectra from the pairs in the group are combined to generate a composite secondary mass spectrum.